Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.56 +0.29 (+0.61%)
Streaming Delayed Price Updated: 12:38 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
40 41 Next >
News headline image
EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers ↗
VeeCon will bring the best of business, pop culture and Web3 in a multi-day conference hosted by serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) for a 
Via Benzinga
News headline image
3 Stocks to Sell Immediately Based on the French Election Results ↗
Discover why Engie S.A., Sanofi, and Carrefour are prime candidates for divestment post-French elections amid potential policy impacts. 
Via InvestorPlace
News headline image
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
News headline image
Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
News headline image
7 Safe Haven Stocks to Buy Before the Next Market Correction ↗
Discover resilient safe haven stocks to weather economic fluctuations in restaurants, pharmaceuticals, household products, and retail. 
Via InvestorPlace
News headline image
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data ↗
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a... 
Via Benzinga
News headline image
Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes ↗
After pulling back following May's "Sanofi surge," don't rule out the potential for further needle-moving news with Novavax stock. 
Via InvestorPlace
News headline image
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims ↗
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
Via Benzinga
Topics Lawsuit
News headline image
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024. ↗
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant ↗
Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany's healthcare sector. Recent investments by Daiichi Sankyo and Eli Lilly... 
Via Benzinga
News headline image
Where Will Novavax Be in 1 Year? ↗
We will know a lot more about the vaccine maker's long-term prospects in 12 months. 
Via The Motley Fool
News headline image
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product ↗
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. 
Via Benzinga
News headline image
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today? ↗
Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi. 
Via InvestorPlace
News headline image
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC ↗
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
Via Benzinga
News headline image
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer ↗
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. 
Via Benzinga
Topics Lawsuit
News headline image
Is It Too Late to Buy Novavax Stock? ↗
Shares of the vaccine maker are trading up 230% this year. 
Via The Motley Fool
News headline image
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks ↗
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily
News headline image
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club ↗
Enthusiasm is growing for a looming approval in COPD treatment. 
Via Investor's Business Daily
News headline image
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge ↗
The integration of AI and healthcare is well underway. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Bull Market and Beyond: 3 Stocks Just Waiting to Soar ↗
These pharma and biotech players could become long-term winners. 
Via The Motley Fool
News headline image
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK ↗
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
News headline image
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. 
Via InvestorPlace
News headline image
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash ↗
Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty. 
Via InvestorPlace
News headline image
Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients ↗
Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients. 
Via Benzinga
News headline image
3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth ↗
Explore three reliable dividend growth stocks for June 2024 to expand your investment profits for the second half of the year. 
Via InvestorPlace
News headline image
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward ↗
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022... 
Via Benzinga
Topics Lawsuit
News headline image
Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet ↗
These are the overpriced growth stocks to sell and buy after these names corrected by 20% to 30% in the coming quarters. 
Via InvestorPlace
News headline image
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease ↗
The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.